Recombinant Herpes Zoster Vaccine Lowers Shingles Complication Risk in Patients with Inflammatory Bowel Disease
- PMID: 40623013
- DOI: 10.1093/ecco-jcc/jjaf116
Recombinant Herpes Zoster Vaccine Lowers Shingles Complication Risk in Patients with Inflammatory Bowel Disease
Abstract
Background: Patients with inflammatory bowel disease (IBD) are at increased risk of herpes zoster (HZ) due to innate immune abnormalities in patients with IBD and use of immunosuppressive therapy. The recombinant zoster vaccine (RZV) is recommended, but its efficacy in preventing recurrent HZ among patients with IBD is not well established.
Methods: Using data from the TriNetX Linked Network, we conducted a retrospective cohort study of adults (≥18 years) with IBD and a prior uncomplicated HZ episode. Patients with IBD who received RZV were propensity score-matched 1:1 with those who did not. The primary outcome was subsequent HZ complications. Secondary outcomes included subtypes of HZ complications and recurrent uncomplicated HZ. Hazard ratios (HRs) and 95% CIs were estimated via Cox proportional hazards models.
Results: After matching, 1,260 vaccinated and 1,260 unvaccinated patients with IBD were included. Compared to the unvaccinated cohort, patients receiving RZV had a significantly reduced incidence of HZ complications (7.4% vs. 14.5%; HR, 0.75; 95% CI, 0.58-0.97; p = 0.028). Postherpetic neuralgia was notably decreased (5.8% vs. 12.5%; HR, 0.66; p = 0.010), and no central nervous system involvement occurred among vaccinated patients. Protective effects were more pronounced in patients with ulcerative colitis, females, and those not receiving immunosuppressive therapy.
Conclusions: RZV substantially lowers the risk of HZ complications in patients with IBD, offering significant clinical benefits to those at high risk due to immunosuppression. These findings underscore the importance of RZV as part of preventive care strategies in patients with IBD.
Keywords: Herpes Zoster Complications; Inflammatory Bowel Disease; Propensity Score Matching; Recombinant Zoster Vaccine; Vaccination Efficacy.
© The Author(s) 2025. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Similar articles
-
Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: a retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative Network.EClinicalMedicine. 2025 Jun 25;85:103319. doi: 10.1016/j.eclinm.2025.103319. eCollection 2025 Jul. EClinicalMedicine. 2025. PMID: 40656648 Free PMC article.
-
Risk of herpes zoster and postherpetic neuralgia in patients with psoriasis treated with biologics: a nationwide study using a target trial emulation framework.Br J Dermatol. 2025 Jun 20;193(1):105-114. doi: 10.1093/bjd/ljaf101. Br J Dermatol. 2025. PMID: 40112174
-
Risk of Herpes Zoster Ophthalmicus Recurrence After Recombinant Zoster Vaccination.JAMA Ophthalmol. 2024 Mar 1;142(3):249-256. doi: 10.1001/jamaophthalmol.2023.6830. JAMA Ophthalmol. 2024. PMID: 38358762 Free PMC article.
-
Vaccines for preventing herpes zoster in older adults.Cochrane Database Syst Rev. 2016 Mar 3;3(3):CD008858. doi: 10.1002/14651858.CD008858.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2019 Nov 7;2019(11). doi: 10.1002/14651858.CD008858.pub4. PMID: 26937872 Free PMC article. Updated.
-
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2. Cochrane Database Syst Rev. 2021. PMID: 34844288 Free PMC article.
LinkOut - more resources
Full Text Sources